Thursday, April 1, 2010

MDRNA Acquires Cequent Pharmaceuticals

Bothell-based MDRNA said Thursday that it has acquired Cequent Pharmaceuticals, a developer of RNAi-based therapeutics, in a deal worth $46M in stock. According to MDRNA, the acquisition will expand its oncology pipeline, and also provide the firm with multiple proprietary RNAi drug discovery platforms. MDRNA said the combined company will be headquartered in Bothell, with offices in Cambridge.